Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 387

1.

Computational immune monitoring reveals abnormal double negative T cells present across human tumor types.

Greenplate AR, McClanahan DD, Oberholtzer BK, Doxie DB, Roe CE, Diggins KE, Leelatian N, Rasmussen ML, Kelley MC, Gama V, Siska PJ, Rathmell JC, Ferrell PB, Johnson DB, Irish JM.

Cancer Immunol Res. 2018 Nov 9. pii: canimm.0692.2017. doi: 10.1158/2326-6066.CIR-17-0692. [Epub ahead of print]

PMID:
30413431
2.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
3.

Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection.

Tio M, Rai R, Ezeoke OM, McQuade JL, Zimmer L, Khoo C, Park JJ, Spain L, Turajlic S, Ardolino L, Yip D, Goldinger SM, Cohen JV, Millward M, Atkinson V, Kane AY, Ascierto PA, Garbe C, Gutzmer R, Johnson DB, Rizvi HA, Joshua AM, Hellmann MD, Long GV, Menzies AM.

Eur J Cancer. 2018 Oct 19;104:137-144. doi: 10.1016/j.ejca.2018.09.017. [Epub ahead of print]

PMID:
30347289
4.

Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes.

Wright JJ, Salem JE, Johnson DB, Lebrun-Vignes B, Stamatouli A, Thomas JW, Herold KC, Moslehi J, Powers AC.

Diabetes Care. 2018 Oct 10. pii: dc181465. doi: 10.2337/dc18-1465. [Epub ahead of print] No abstract available.

PMID:
30305348
5.

Biomechanical Assessment of Torsional Stiffness in a Supracondylar Humerus Fracture Model.

Wallace M, Johnson DB, Pierce W, Iobst C, Riccio A, Wimberly RL.

J Pediatr Orthop. 2018 Oct 8. doi: 10.1097/BPO.0000000000001270. [Epub ahead of print]

PMID:
30300279
6.

Immune Checkpoint Inhibitor Toxicity in 2018.

Johnson DB, Chandra S, Sosman JA.

JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995. No abstract available.

PMID:
30286224
7.

Identification of trehalose as a compatible solute in different species of acidophilic bacteria.

Galleguillos PA, Grail BM, Hallberg KB, Demergasso CS, Johnson DB.

J Microbiol. 2018 Oct;56(10):727-733. doi: 10.1007/s12275-018-8176-2. Epub 2018 Sep 28.

PMID:
30267316
8.

An Assessment of Perceived Barriers to Farmers' Market Access.

Ritter G, Walkinshaw LP, Quinn EL, Ickes S, Johnson DB.

J Nutr Educ Behav. 2018 Sep 21. pii: S1499-4046(18)30707-3. doi: 10.1016/j.jneb.2018.07.020. [Epub ahead of print]

PMID:
30249521
9.

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB.

JAMA Oncol. 2018 Sep 13. doi: 10.1001/jamaoncol.2018.3923. [Epub ahead of print]

PMID:
30242316
10.
11.

Reporting of immune checkpoint inhibitor-associated myocarditis - Authors' reply.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB.

Lancet. 2018 Aug 4;392(10145):384-385. doi: 10.1016/S0140-6736(18)31556-3. No abstract available.

PMID:
30102170
12.

The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.

Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA, Verma AK.

JCI Insight. 2018 Jul 25;3(14). pii: 120422. doi: 10.1172/jci.insight.120422. [Epub ahead of print]

13.

Class Matters: Sensitivity of BRAF-Mutant Melanoma to MAPK Inhibition.

Johnson DB, Dahlman KB.

Clin Cancer Res. 2018 Jul 24. doi: 10.1158/1078-0432.CCR-18-1795. [Epub ahead of print]

PMID:
30042206
14.

Biomarkers for immune therapy in melanoma.

Johnson DB, Chon J, Johnson MR, Balko JM.

Semin Cutan Med Surg. 2018 Jun;37(2):120-126. doi: 10.12788/j.sder.2018.019.

PMID:
30040089
15.

The significance of pH in dictating the relative toxicities of chloride and copper to acidophilic bacteria.

Falagán C, Johnson DB.

Res Microbiol. 2018 Jul 19. pii: S0923-2508(18)30118-9. doi: 10.1016/j.resmic.2018.07.004. [Epub ahead of print]

16.

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma.

Johnson DB, Bordeaux J, Kim JY, Vaupel C, Rimm DL, Ho TH, Joseph RW, Daud AI, Conry RM, Gaughan EM, Hernandez-Aya LF, Dimou A, Funchain P, Smithy J, Witte JS, McKee SB, Ko J, Wrangle JM, Dabbas B, Tangri S, Lameh J, Hall J, Markowitz J, Balko JM, Dakappagari N.

Clin Cancer Res. 2018 Nov 1;24(21):5250-5260. doi: 10.1158/1078-0432.CCR-18-0309. Epub 2018 Jul 18.

PMID:
30021908
17.

Effects of a Behavioral Economics Intervention on Food Choice and Food Consumption in Middle-School and High-School Cafeterias.

Quinn EL, Johnson DB, Podrabsky M, Saelens BE, Bignell W, Krieger J.

Prev Chronic Dis. 2018 Jul 5;15:E91. doi: 10.5888/pcd15.170377.

18.

Toxicities and outcomes: Do steroids matter?

Johnson DB.

Cancer. 2018 Sep 15;124(18):3638-3640. doi: 10.1002/cncr.31627. Epub 2018 Jul 5. No abstract available.

PMID:
29975416
19.

Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials.

Johnson DB, Daniels AB.

JAMA Ophthalmol. 2018 Sep 1;136(9):986-988. doi: 10.1001/jamaophthalmol.2018.1813. No abstract available.

PMID:
29955760
20.

Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations.

Kugel CH 3rd, Douglass SM, Webster MR, Kaur A, Liu Q, Yin X, Weiss SA, Darvishian F, Al-Rohil RN, Ndoye A, Behera R, Alicea GM, Ecker BL, Fane M, Allegrezza MJ, Svoronos N, Kumar V, Wang DY, Somasundaram R, Hu-Lieskovan S, Ozgun A, Herlyn M, Conejo-Garcia JR, Gabrilovich D, Stone EL, Nowicki TS, Sosman J, Rai R, Carlino MS, Long GV, Marais R, Ribas A, Eroglu Z, Davies MA, Schilling B, Schadendorf D, Xu W, Amaravadi RK, Menzies AM, McQuade JL, Johnson DB, Osman I, Weeraratna AT.

Clin Cancer Res. 2018 Nov 1;24(21):5347-5356. doi: 10.1158/1078-0432.CCR-18-1116. Epub 2018 Jun 13.

PMID:
29898988
21.

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.

Luo N, Formisano L, Gonzalez-Ericsson PI, Sanchez V, Dean PT, Opalenik SR, Sanders ME, Cook RS, Arteaga CL, Johnson DB, Balko JM.

Oncoimmunology. 2018 Mar 6;7(6):e1438106. doi: 10.1080/2162402X.2018.1438106. eCollection 2018.

22.

Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune Disease.

Johnson DB, Beckermann KE, Wang DY.

Oncology (Williston Park). 2018 Apr 15;32(4):190-4.

23.

Melanoma: What do all the mutations mean?

Davis EJ, Johnson DB, Sosman JA, Chandra S.

Cancer. 2018 Sep 1;124(17):3490-3499. doi: 10.1002/cncr.31345. Epub 2018 Apr 17. Review.

PMID:
29663336
24.

Microbial diversity and biomarker analysis of modern freshwater microbialites from Laguna Bacalar, Mexico.

Johnson DB, Beddows PA, Flynn TM, Osburn MR.

Geobiology. 2018 May;16(3):319-337. doi: 10.1111/gbi.12283. Epub 2018 Apr 15.

PMID:
29656514
25.

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.

Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB.

Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6. No abstract available.

PMID:
29536852
26.

Bursitis, Ischial.

Johnson DB, Gossman WG.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jan 2.

27.

Dexamethasone.

Johnson DB, Bhimji SS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jan 24.

28.

Topiramate And Phentermine .

Johnson DB, Bhimji SS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Sep 24.

29.

Flutamide.

Johnson DB, Bhimji SS.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jun 26.

30.

Albuterol.

Johnson DB, Bounds CG.

StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-.
2018 Jan 7.

31.

An Evaluation of Washington State SNAP-Ed Farmers' Market Initiatives and SNAP Participant Behaviors.

Walkinshaw LP, Quinn EL, Rocha A, Johnson DB.

J Nutr Educ Behav. 2018 Jun;50(6):536-546. doi: 10.1016/j.jneb.2018.01.003. Epub 2018 Mar 1.

PMID:
29478951
32.

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, Rubinstein SM, Rooney I, Musib L, Budha N, Hsu J, Nowicki TS, Avila A, Haas T, Puligandla M, Lee S, Fang S, Wargo JA, Gershenwald JE, Lee JE, Hwu P, Chapman PB, Sosman JA, Schadendorf D, Grob JJ, Flaherty KT, Walker D, Yan Y, McKenna E, Legos JJ, Carlino MS, Ribas A, Kirkwood JM, Long GV, Johnson DB, Menzies AM, Davies MA.

Lancet Oncol. 2018 Mar;19(3):310-322. doi: 10.1016/S1470-2045(18)30078-0. Epub 2018 Feb 12.

33.

Microbiomes in extremely acidic environments: functionalities and interactions that allow survival and growth of prokaryotes at low pH.

Quatrini R, Johnson DB.

Curr Opin Microbiol. 2018 Jun;43:139-147. doi: 10.1016/j.mib.2018.01.011. Epub 2018 Feb 6. Review.

34.

Salt Stress-Induced Loss of Iron Oxidoreduction Activities and Reacquisition of That Phenotype Depend on rus Operon Transcription in Acidithiobacillus ferridurans.

Bonnefoy V, Grail BM, Johnson DB.

Appl Environ Microbiol. 2018 Mar 19;84(7). pii: e02795-17. doi: 10.1128/AEM.02795-17. Print 2018 Apr 1.

35.

Toxicities Associated With PD-1/PD-L1 Blockade.

Wang DY, Johnson DB, Davis EJ.

Cancer J. 2018 Jan/Feb;24(1):36-40. doi: 10.1097/PPO.0000000000000296.

PMID:
29360726
36.

Growth of Leptospirillum ferriphilum in sulfur medium in co-culture with Acidithiobacillus caldus.

Smith SL, Johnson DB.

Extremophiles. 2018 Mar;22(2):327-333. doi: 10.1007/s00792-018-1001-3. Epub 2018 Jan 12.

37.

High response rate to PD-1 blockade in desmoplastic melanomas.

Eroglu Z, Zaretsky JM, Hu-Lieskovan S, Kim DW, Algazi A, Johnson DB, Liniker E, Ben Kong, Munhoz R, Rapisuwon S, Gherardini PF, Chmielowski B, Wang X, Shintaku IP, Wei C, Sosman JA, Joseph RW, Postow MA, Carlino MS, Hwu WJ, Scolyer RA, Messina J, Cochran AJ, Long GV, Ribas A.

Nature. 2018 Jan 18;553(7688):347-350. doi: 10.1038/nature25187. Epub 2018 Jan 10.

38.

Draft genome sequence of the type strain of the sulfur-oxidizing acidophile, Acidithiobacillus albertensis (DSM 14366).

Castro M, Moya-Beltrán A, Covarrubias PC, Gonzalez M, Cardenas JP, Issotta F, Nuñez H, Acuña LG, Encina G, Holmes DS, Johnson DB, Quatrini R.

Stand Genomic Sci. 2017 Dec 15;12:77. doi: 10.1186/s40793-017-0282-y. eCollection 2017.

39.

BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy.

Johnson DB, Childress MA, Chalmers ZR, Frampton GM, Ali SM, Rubinstein SM, Fabrizio D, Ross JS, Balasubramanian S, Miller VA, Stephens PJ, Sosman JA, Lovly CM.

Pigment Cell Melanoma Res. 2018 May;31(3):432-436. doi: 10.1111/pcmr.12674. Epub 2017 Dec 16.

40.

Smoldering myocarditis following immune checkpoint blockade.

Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, Gertler AS, Moslehi JJ, Conry RM.

J Immunother Cancer. 2017 Nov 21;5(1):91. doi: 10.1186/s40425-017-0296-4.

41.

Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.

Wang DY, Ye F, Zhao S, Johnson DB.

Oncoimmunology. 2017 Jul 5;6(10):e1344805. doi: 10.1080/2162402X.2017.1344805. eCollection 2017.

42.

Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.

Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN.

Ann Oncol. 2018 Jan 1;29(1):250-255. doi: 10.1093/annonc/mdx642.

PMID:
29045547
43.

MDM2 Antagonists Counteract Drug-Induced DNA Damage.

Vilgelm AE, Cobb P, Malikayil K, Flaherty D, Andrew Johnson C, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnson DB, Kelley MC, Chen SC, Ayers GD, Richmond A.

EBioMedicine. 2017 Oct;24:43-55. doi: 10.1016/j.ebiom.2017.09.016. Epub 2017 Sep 19.

44.

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.

Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, Gasal E, Mookerjee B, Weber J, Flaherty KT.

J Clin Oncol. 2018 Mar 1;36(7):667-673. doi: 10.1200/JCO.2017.74.1025. Epub 2017 Oct 9.

PMID:
28991513
45.

Emerging biomarkers for cancer immunotherapy in melanoma.

Axelrod ML, Johnson DB, Balko JM.

Semin Cancer Biol. 2018 Oct;52(Pt 2):207-215. doi: 10.1016/j.semcancer.2017.09.004. Epub 2017 Sep 14. Review.

PMID:
28917578
46.

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.

Song C, Piva M, Sun L, Hong A, Moriceau G, Kong X, Zhang H, Lomeli S, Qian J, Yu CC, Damoiseaux R, Kelley MC, Dahlman KB, Scumpia PO, Sosman JA, Johnson DB, Ribas A, Hugo W, Lo RS.

Cancer Discov. 2017 Nov;7(11):1248-1265. doi: 10.1158/2159-8290.CD-17-0401. Epub 2017 Sep 1.

47.

Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.

Zhou AY, Johnson DB.

Am J Clin Dermatol. 2018 Apr;19(2):181-193. doi: 10.1007/s40257-017-0320-y. Review.

PMID:
28861871
48.

Enabling a genetically informed approach to cancer medicine: evaluation of the impact of comprehensive tumor sequencing.

Davis EJ, Johnson DB.

Per Med. 2017 May;14(3):189-192. doi: 10.2217/pme-2017-0014. Epub 2017 May 5.

49.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

50.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

Supplemental Content

Loading ...
Support Center